DONATE TODAY HOT TOPICS ▶ Climate Change     Undoing The New Deal     The Real Baltimore     Reality Asserts Itself     United Kingdom    

  October 2, 2015

Why Drug Prices Are Out of Control, And What We Can Do About It

Jamie Love of Knowledge Ecology International told the Real News that our system does little to curb outrageous drug prices, and it's not because there aren't good alternatives
Members don't see ads. If you are a member, and you're seeing this appeal, click here

Share to Facebook Share to Twitter

Because news is only as honest as the intentions of those who report it. - Joel L.
Log in and tell us why you support TRNN


Well, it used to--it used to be a lot more journalism around these various scandals. Certainly the '80s and the '90s you'd be, you saw more investigative work on these kind of corporate malfeasance stories, or drug pricing scandals and things like that.

I think one thing that's changed now is a lot of people are insured. And when there's a lot of people are insured there may be a problem in the price of the drug, but they may not experience it themselves. So if a drug goes from $13 to $750 a pill, or if a treatment cost $84,000 or $184,000, what the patient's really looking at is what, what their co-payment is. And as long as they have insurance and the insurance covers it, they don't really complain too much. What they really want to know is are they in or out of the system. It's pretty painful if you're out. But if you're in then you just feel like, okay, it's not my problem anymore.

Collectively it's evryone's problem. I mean, the reason why we pay so much for insurance is because it's just become, prices have become out of control.

Eventually you begin to see sort of the predictable backlash. Which is to say, it's harder and harder to get certain products covered by insurance, the co-payments are higher, and the--you can't experiment with cancer drugs on patients as easily because the insurance company won't allow you to try a drug that doesn't have a strong approval even though you might benefit from it.

If you think we have about a trillion dollars of a drug market, less than 8 percent of that is reinvested by the private sector back into R&D for new drugs. Of that 8 percent that's reinvested less than half of that is invested in products that have any kind of medical benefits that anybody cares about. There's a certain amount of money that's just disguised bribes to doctors. And consulting fees on clinical trials that is really just about getting favor with doctors that prescribe your products. All of that's good from a commercial point of view but it doesn't really do anything for medical outcomes.

One sort of interpretation is that the White House figures that we're, Americans, we're the sellers of drugs. We have companies like Pfizer and Merck and Johnson and Johnson. So we should push for high prices everywhere because we would benefit more than it would hurt us. The pharmaceutical industry is not the whole U.S. economy. And yet for the trade agreement they're almost the whole enchilada. I mean, like, basically the biggest demand the United States has in the trade agreement is to give big pharma what it wants. That's coming at the expense of things for auto workers and for other sectors of the economy that are going to be disadvantaged by the trade agreement.

If you look at the CEOs of companies, old school would be CEOs that knew something about the industry itself, that worked in, you know, as an engineer or as a, they were doctors or things like that. Like Roy Vagelos from, is that how you say his name? Former CEO of Merck, was one of these sort of old-school guys. Now you see these people that come in. Pfizer for a while they had a CEO that came out of business school, then they had a lawyer running the firm. Novartis fired one of their guys and replaced him with a ketchup salesman. I mean, now people running the firms are just, you know, their basically expertise is in marketing, sometimes finance. And it's just, they're just, they're just trying to--you know, they have assets. The assets are whatever products they have, which are whatever drugs they have. And they just figure out how to make as much money from them as possible.

Pharmaceutical drugs should be generic drugs. They should be generic drugs all the time. You'd have to replace, taking away the monopoly system. You'd have to create a separate way to pay off the innovation. And that's not that difficult to do for drugs. You can have a fund that rewards innovation, that looks the the same type of information that's used right now as a reality check on, on reimbursements for high prices. Just to make it more concrete, you can de-link the way that you finance R&D from the price of the drug that the patient sees.


DISCLAIMER: Please note that transcripts for The Real News Network are typed from a recording of the program. TRNN cannot guarantee their complete accuracy.


Our automatic spam filter blocks comments with multiple links and multiple users using the same IP address. Please make thoughtful comments with minimal links using only one user name. If you think your comment has been mistakenly removed please email us at

latest stories

Guns, Toxic Masculinity, and the Alt-Right
Zuma's Catastrophic Presidency Ends in Forced Resignation
Brother of Crooked Cop Says He Knows Who Killed Detective Suiter
Israeli Strikes in Egypt Kept Secret for Years
As the Opioid Crisis Deepens, Will Maryland Democrats Vote to Save Lives?
The Free Market Threat to Democracy
Finding a SALT Tax Deduction Workaround
Leader of Neo-Nazi Militia Says MAGA Hat-Wearing Florida Shooter Trained with Them
Charter School Principal: No Evidence Privatization Is Better For Students
Max Blumenthal in Gaza: Netanyahu Faces Scandal, Palestinians a Crisis
Trump's Infrastructure Fantasy a Gift to His Donors
Netanyahu Could Fall for Corruption, Not War Crimes
Climate Change Costs Insurance Companies Billions, And Price is Rising
Trump's Budget Declares War on Forgotten America
West Virginia Woman Removed From Legislature After Exposing Fossil Fuel Contributions to Lawmakers
Leftist Hopeful's Lead Signals Upheaval for Mexico
Wilkerson: From Trump Parade to Budget, There's 'Too Much Military'
Trump's Budget and Infrastructure Plans Threaten Environment
Catharsis and Corruption in Wake of Dirty Cop Conviction
Confronting Trudeau on Climate Lies and Kinder Morgan Pipeline
Two Cops Found Guilty In Massive Police Corruption Scandal
In First Black Police Chief's Appeal, Judges Weigh Prosecutorial Misconduct, Discrimination
City Council Committee Advances Styrofoam Ban, But Delays Implementation
Trump Privatizes America
Is the Oil Industry Canada's 'Deep State'?
FBI Says It Has No Records on Violent Neo-Nazi Group, While Surveilling Antifascists and Black Activists
Democracy in Crisis: The FBI and Dirty Cops
'Normalizing' Britain's Interest Rates by Raising Them May Slow Economy
Koreas Talk Peace, But Does Trump Want War?
Guilty Verdict in Gun Trace Task Force Corruption Trial,, The Real News Network, Real News Network, The Real News, Real News, Real News For Real People, IWT are trademarks and service marks of Independent World Television inc. "The Real News" is the flagship show of IWT and The Real News Network.

All original content on this site is copyright of The Real News Network. Click here for more

Problems with this site? Please let us know

Web Design, Web Development and Managed Hosting